Showing results (2851-2860 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|March 13, 2018
Phase II trial of ifosfamide in combination with the VEGFR inhibitor sorafenib in advanced soft tissue sarcoma: a Spanish group for research on sarcomas (GEIS) studyXavier García Del Muro, Joan Maurel, Javier Martínez Trufero, et al.
Investigational New Drugs|February 2, 2018
SMER28 is a mTOR-independent small molecule enhancer of autophagy that protects mouse bone marrow and liver against radiotherapyMichael I Koukourakis, Alexandra Giatromanolaki, Konstantina Fylaktakidou, et al.
Investigational New Drugs|January 1, 1986
Regional fibrosis after intraperitoneal administration of mafosfamideJ D Roberts, R A Newman, P J Kimberly, et al.
Investigational New Drugs|March 7, 2018
Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studiesHerbert Hurwitz, Eric Van Cutsem, Johanna Bendell, et al.
Investigational New Drugs|February 25, 2018
A phase 2 study of OSI-906 (linsitinib, an insulin-like growth factor receptor-1 inhibitor) in patients with asymptomatic or mildly symptomatic (non-opioid requiring) metastatic castrate resistant prostate cancer (CRPC)Pedro Barata, Matthew Cooney, Allison Tyler, et al.
Investigational New Drugs|November 16, 2017
LFM-A13, a potent inhibitor of polo-like kinase, inhibits breast carcinogenesis by suppressing proliferation activity and inducing apoptosis in breast tumors of miceKazim Sahin, Mehmet Tuzcu, Mehmet Yabas, et al.
Investigational New Drugs|October 4, 2017
Phase I study of the combination of quinacrine and erlotinib in patients with locally advanced or metastatic non small cell lung cancerPriyanka Bhateja, Afshin Dowlati, Neelesh Sharma
Investigational New Drugs|October 12, 2017
Gastrointestinal perforation related to lenvatinib, an anti-angiogenic inhibitor that targets multiple receptor tyrosine kinases, in a patient with metastatic thyroid cancerEmi Date, Kunio Okamoto, Souichi Fumita, et al.
Investigational New Drugs|October 10, 2017
Dual Src and EGFR inhibition in combination with gemcitabine in advanced pancreatic cancer: phase I results : A phase I clinical trialDana B Cardin, Laura W Goff, Emily Chan, et al.
Investigational New Drugs|December 18, 2018
Cyclodextrin polymers decorated with RGD peptide as delivery systems for targeted anti-cancer chemotherapyMaurizio Viale, Rita Tosto, Valentina Giglio, et al.
Pageof 372